Generalized Anxiety Disorder Epidemiology

Generalized Anxiety Disorder (GAD) Insights and Trends

• GAD is more prevalent in females than males, with approximately 3.4% of females and 1.9% of males affected in the US.
• In the United States, around 5.7% of adults experience GAD in their lifetime, while approximately 2.7% have diagnosed GAD.
• In Europe, Germany reports ~1.5% prevalence in the general population, rising to ~5.3% in primary care settings, indicating higher detection in clinical environments.
• In the US, among diagnosed patients, 44.6% experience moderate symptoms, followed by 32.3% severe and 23.1% mild cases, reflecting a significant disease burden.
• GAD prevalence is higher in the working-age population (30–59 years), with the highest diagnosed cases observed in the 45–59 age group.

Generalized Anxiety Disorder Epidemiology Forecast in the 7MM

• 2025 Incident Cases of GAD : ~XX
• GAD Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Generalized Anxiety Disorder Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the GAD, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Generalized Anxiety Disorder Understanding and Diagnosis Algorithm

Generalized Anxiety Disorder Overview and Diagnosis

Generalized Anxiety Disorder is a chronic psychiatric disorder characterized by excessive, persistent, and uncontrollable worry about multiple aspects of daily life for at least six months, leading to significant functional impairment. It is commonly associated with symptoms such as restlessness, fatigue, irritability, muscle tension, poor concentration, and sleep disturbances. GAD is diagnosed clinically based on DSM-5 criteria, with assessment of symptom duration, severity, and exclusion of medical or substance-induced causes. Despite available treatments including SSRIs, SNRIs, and cognitive behavioral therapy (CBT), GAD remains highly prevalent and is often linked with comorbid depression and other anxiety disorders, driven by genetic, neurobiological, and environmental risk factors.

Diagnosis of GAD is primarily clinical and based on DSM-5 criteria, requiring the presence of excessive, uncontrollable worry occurring more days than not for at least six months, along with associated cognitive, emotional, and physical symptoms. Assessment includes evaluation of symptom severity, duration, and functional impairment, alongside screening tools such as standardized anxiety rating scales. It is essential to exclude medical, neurological, or substance-induced causes that may mimic anxiety symptoms through clinical history, physical examination, and relevant laboratory tests when indicated. Early and accurate diagnosis is important to ensure timely initiation of appropriate pharmacological and psychological interventions, improving long-term outcomes and reducing disease burden.

Further details are provided in the report.

Generalized Anxiety Disorder Epidemiology

Key Findings from GAD Epidemiological Analysis and Forecast 

• GAD is more prevalent in females than males, with approximately 3.4% of females and 1.9% of males affected in the US.
• In the United States, around 5.7% of adults experience GAD in their lifetime, while approximately 2.7% have diagnosed GAD.
• In Europe, Germany reports ~1.5% prevalence in the general population, rising to ~5.3% in primary care settings, indicating higher detection in clinical environments.
• In the US, among diagnosed patients, 44.6% experience moderate symptoms, followed by 32.3% severe and 23.1% mild cases, reflecting a significant disease burden.
• GAD prevalence is higher in the working-age population (30–59 years), with the highest diagnosed cases observed in the 45–59 age group.
• In Japan, GAD is more common in younger adults, with prevalence declining with age to ≤7% in individuals aged ≥60 years, and slightly higher rates in females.
• In the UK, approximately two-thirds of diagnosed GAD patients are female, highlighting a strong gender disparity.
• The diagnosed prevalent and treated population of GAD is expected to increase over the forecast period, driven by rising mental health awareness, improved diagnosis rates, reduced stigma, expanded healthcare access, and greater adoption of both pharmacological and behavioral therapies, including telemedicine enabled care delivery.

Scope of the Report

• The report covers a segment of a descriptive overview of GAD, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression. 

Report Insights

GAD Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of GAD? What will be the growth opportunities across the 7MM concerning the patient population with GAD?
• What is the historical and forecasted GAD patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.